Inovio Pharmaceuticals (AMEX:INO) said Monday its SynCon vaccine induced a positive T-Cell immune response in mice with diseases caused by the human papillomavirus (HPV) types 6 and 11, broadening the company's reach with the synthetic vaccine.
Inovio's SynCon technology allows it to design synthetic
vaccines with the potential to protect against unmatched sub-types and
strains of pathogens, including newly emergent, unknown strains of a
virus that will periodically emerge through mutation, as in the case of
the HPV virus.
The vaccine for these two types joins the
company's existing vaccines for types 16 and 18, which is currently in a
phase two clinical study.
The results were published in Human
Vaccines & Immunotherapeutic, a peer-reviewed paper, titled
"Induction of robust cellular immunity against HPV6 and HPV11 in mice by
DNA vaccine encoding for E6/E7 antigen".
Inovio president and
CEO, Dr. J. Joseph Kim said: "Over a dozen HPV types are recognized as
causing cancers and other diseases, with a significant health need and
business opportunity for therapeutic vaccines to address these
"With the best-in-class T-cell responses generated
by VGX-3100 in early human studies, our goal is to create a family of
therapeutic vaccines targeting most significant diseases caused by HPV
infection, including cervical cancer and dysplasia, vulvar dysplasia,
head and neck cancer, and other cancers.
"This study demonstrates our ability to readily extend our therapeutic solutions to diseases caused by different HPV types.
"Importantly, our clinical experience with VGX-3100 may also help streamline the regulatory path for these related vaccines."
new SynCon vaccines were developed to target antigens E6 and E7 of HPV 6
and HPV 11. The vaccines were then modified to increase gene expression
and production of the antigenic protein.
The product was
administered using the company's proprietary electroporation delivery
system, which has proven to boost immune responses by up to 100-fold.
The HPV virus is the potentially deadly virus behind such diseases as head and neck cancers, and genital warts, among others.
6 and 11 in particular are the major cause of recurrent respiratory
papillomatosis, which is commonly manifested in warts in the airway, as
well as genital warts. The strains are also associated with ear, nose
and throat malignancies, carcinoma of the lung, tonsil and larynx, and
low-grade cervical lesions.
In addition to the treatment of HPV,
Inovio's SynCon vaccines are also undergoing clinical evaluations to
treat the influenza virus, cervical dysplasia, leukemia, the hepatitis C
virus, and HIV.
On the AMEX, Inovio shares spiked 8.28 percent in premarket trading, to $0.667 per share as of 8:12 am EDT.